Amolimogene bepiplasmid, a DNA-based therapeutic encoding the E6 and E7 epitopes from HPV, for cervical and anal dysplasia [0.03%]
阿莫林莫吉恩倍吡普雷米德，一种基于DNA的疗法，用于治疗宫颈和肛门的上皮内瘤变，包含HPV的E6和E7表位
Luis M Alvarez-Salas
Luis M Alvarez-Salas
MGI Pharma Biologics is developing amolimogene bepiplasmid as a potential therapy for HPV-associated diseases, including cervical dysplasia. Amolimogene bepiplasmid is a polymer-encapsulated DNA vaccine consisting of a plasmid expressing a ...
MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases [0.03%]
自体骨骼肌母细胞疗法治疗心血管疾病
Husnain Kh Haider,Ye Lei,Muhammad Ashraf
Husnain Kh Haider
Cell therapy is fast emerging as a potential therapeutic option in cardiovascular therapeutics. Because of their inherent myogenic differentiation potential, skeletal myoblasts (SkMs) have been extensively assessed in preclinical and clinic...
Protein biomarkers in cancer: natural glycoprotein microarray approaches [0.03%]
癌症中的蛋白质生物标志物：天然糖蛋白微阵列方法
Jia Zhao,Tasneem H Patwa,David M Lubman et al.
Jia Zhao et al.
Protein glycosylation is the most versatile and common protein modification and plays important roles in various biological processes and disease progression. In this review, the development of microarray technology for protein glycosylatio...
Thomas M Bridges,Richard Williams,Craig W Lindsley
Thomas M Bridges
Inhibitors of Gly transporter type-1 (GlyT1) for the treatment of schizophrenia have been pursued on the basis of the NMDA receptor (R) hypofunction hypothesis, which stems largely from the observation that NMDAR antagonists induce symptoms...
Novel approaches in anti-angiogenic treatment targeting endothelial F-actin: a new anti-angiogenic strategy? [0.03%]
针对内皮F肌动蛋白的抗血管生成治疗新策略：新的抗血管生成治疗方法？
Lilja Thoenes,Michael Günther
Lilja Thoenes
As a functional blood supply is crucial for growth of solid tumors, the development of anticancer agents to inhibit the formation of new tumor blood vessels is an area of extensive research. Endothelial cell motility driven by the dynamics ...
Bradley P Shelton,Neil L Misso,Odette M Shaw et al.
Bradley P Shelton et al.
Cancer is the second leading cause of death in industrialized countries, with epithelial cell cancers (carcinomas) representing approximately 85% of all diagnosed cancers. The 5-year survival rate for many carcinomas remains low, highlighti...
An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents [0.03%]
风湿性关节炎的药物基因组学研究进展——聚焦肿瘤坏死因子阻断剂
Prabha Ranganathan
Prabha Ranganathan
TNFalpha is a proinflammatory cytokine, which is crucial in the pathogenesis of rheumatoid arthritis (RA). In recent years, biological therapies which block the damaging effects of TNFalpha on synovium and cartilage have been developed. TNF...
Lara M Mangravite,Russell A Wilke,Jiong Zhang et al.
Lara M Mangravite et al.
Statins, which act primarily to lower plasma LDL-cholesterol, are prescribed to reduce cardiovascular disease (CVD) risk, but treatment response is variable. Genetic variation may modify both statin efficacy and susceptibility to statin-ind...
J Todd Auman,Howard L McLeod
J Todd Auman
Clinically and histopathologically similar colorectal cancers exhibit considerable variability in their responses to chemotherapeutics. The advent of genomic technologies has enabled the unbiased determination of changes in DNA and RNA, alt...